SeaStar Medical Reaches Milestone Of 100th QUELIMMUNE Commercial Device As Shipments Begin To Its Third Hospital Customer
SeaStar Medical Reaches Milestone Of 100th QUELIMMUNE Commercial Device As Shipments Begin To Its Third Hospital Customer
SeaStar Medical 達成了 100 個 QUELIMMUNE 商用設備的里程碑，開始向其第三家醫院客戶發貨。
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE to a third hospital customer. QUELIMMUNE is the Company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis.
SeaStar 醫療控股公司（納斯達克:ICU），一傢俱有商業階段的醫療器械公司，正在研發專有解決方案，以減少高炎症對重要器官的影響，已開始向第三家醫院客戶運送 QUELIMMUNE。 QUELIMMUNE 是公司用於治療重症監護室（ICU）中急性腎損傷（AKI）和膿毒血癥的選擇性細胞浸潤裝置（SCD）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間